PlainPharmaWatch

CMS Open Payments · Program Year 2024

Boehringer Ingelheim RCV GmbH & Co KG

Boehringer Ingelheim RCV GmbH & Co KG reported $126,893.79 in payments to 12 physicians and teaching hospitals across 70 transactions.

See the rankings → How this is sourced
$126.9K
Total payments
70
Transactions
12
Recipients
−$148.3K
General Payments vs PY2023

Boehringer Ingelheim RCV GmbH & Co KG reported $126,893.79 in payments to 12 physicians and teaching hospitals in CMS Open Payments Program Year 2024 - ranking #1117 of 1,925 reporting manufacturers (0.0% of all US industry payments), averaging $10.6K per recipient across 3 payment categories. Figures are company-reported under the Physician Payments Sunshine Act; a reported payment is a financial relationship, not evidence of wrongdoing.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the editorial team.

The verdict

Boehringer Ingelheim RCV GmbH & Co KG pairs below-median payment volume with a moderately concentrated payment pattern.

#1117
of 1,925 companies
0.0%
of all US industry payments
0.3%
paid to its single top recipient
3
payment categories

Release-over-release change

General Payments changed from PY2023 to PY2024

Boehringer Ingelheim RCV GmbH & Co KG's CMS-reported General Payments decreased by $148.3K (−70.0%) from PY2023 to PY2024. The comparison uses the same CMS manufacturer-by-payment-category summary for both years and excludes research and ownership or investment records.

CMS source labels for this exact identifier: PY2022: BOEHRINGER INGELHEIM RCV GMBH & CO KGPY2023: BOEHRINGER INGELHEIM RCV GMBH & CO KGPY2024: Boehringer Ingelheim RCV GmbH & Co KG. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$212.0KPY2024$63.7K
PY2023
$212,030.09
PY2024
$63,681.10

How Boehringer Ingelheim RCV GmbH & Co KG ranks nationally

Where this company's total reported payments fall within the full national distribution of all 1,925 companies in CMS Open Payments, not just its nearest peers.

Boehringer Ingelheim RCV GmbH & Co KG's total vs. every reporting company

CMS Open Payments, Program Year 2024

$126,894 42nd percentile higher than 42% of 1,925 reporting companies

$9–$28: 3 reporting companies (0%). Below this entry. $28–$87: 10 reporting companies (1%). Below this entry. $87–$270: 20 reporting companies (1%). Below this entry. $270–$838: 41 reporting companies (2%). Below this entry. $838–$2,603: 76 reporting companies (4%). Below this entry. $2,603–$8,084: 114 reporting companies (6%). Below this entry. $8,084–$25,112: 167 reporting companies (9%). Below this entry. $25,112–$78,003: 249 reporting companies (13%). Below this entry. $78,003–$242,294: 295 reporting companies (15%). This entry sits in this band. $242,294–$752,621: 270 reporting companies (14%). Above this entry. $752,621–$2,337,813: 263 reporting companies (14%). Above this entry. $2,337,813–$7,261,783: 200 reporting companies (10%). Above this entry. $7,261,783–$22,556,757: 133 reporting companies (7%). Above this entry. $22,556,757–$70,066,439: 45 reporting companies (2%). Above this entry. $70,066,439–$217,642,369: 26 reporting companies (1%). Above this entry. $217,642,369–$676,046,922: 13 reporting companies (1%). Above this entry. This company $9 $676,046,922 every reporting company, bucketed by value

Each bar is a progressively wider band; taller bars hold more reporting companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source CMS Open Payments · 2024

What the Data Shows for Boehringer Ingelheim RCV GmbH & Co KG

$126,893.79: that is what Boehringer Ingelheim RCV GmbH & Co KG reported in payments to 12 physicians and teaching hospitals during Program Year 2024, spread across 70 transactions ($1.8K per transaction, $10.6K per recipient). The company sits at rank #1117 of 1,925, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.

Of the 3 general-payment categories charted below, "Compensation for Services Other Than Consulting" is the largest at $29.9K across 5 transactions, 23.5% of the company's reported total (see our methodology for how research and ownership payments are reported separately).

General Payment Breakdown by Type

Across 3 types of general payments, Boehringer Ingelheim RCV GmbH & Co KG's largest category was "Compensation for Services Other Than Consulting" at $29.9K - 23.5% of the company's reported total.

How Boehringer Ingelheim RCV GmbH & Co KG divides its payments

General-payment categories, ordered by reported total

1. Compensation for Services…$29.9K2. Travel and Lodging$20.8K3. Consulting Fee$13.0K
Payment Type Amount Transactions
Compensation for Services Other Than Consulting $29.9K 5
Travel and Lodging $20.8K 5
Consulting Fee $13.0K 2

Recipient Concentration in General Payments

The five largest recipient relationships account for $61,731.10 (96.9%) of $63,681.10 in this company's General Payments records across 6 recipients. This is a CMS Open Payments Program Year 2024 General Payments view only: it excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Boehringer Ingelheim RCV GmbH & Co KG

The five named recipients with the highest reported General Payments from this company

Justin M Oldham$21.3KJaved Butler$20.0KMark J Ratain$11.1KDeepak Bhatt$5.6KAdrian Felipe Hernandez$3.9K
  1. 1

    Justin M Oldham

    $21,267.62 across 4 reported transactions

  2. 2

    Javed Butler

    $19,998.48 across 4 reported transactions

  3. 3

    Mark J Ratain

    $11,050.00 across 1 reported transactions

  4. 4

    Deepak Bhatt

    $5,565.00 across 1 reported transactions

  5. 5

    Adrian Felipe Hernandez

    $3,850.00 across 1 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Payment Size Analysis

Average transaction size: $1.8K. Average per recipient: $10.6K.

Total Amount

$126,893.79

Avg per Transaction

$1.8K

Avg per Recipient

$10.6K

Payment Transparency Context

What is the Sunshine Act?

The Physician Payments Sunshine Act (part of the Affordable Care Act) requires pharmaceutical and medical device manufacturers to report payments and transfers of value to physicians and teaching hospitals. These payments can include consulting fees, research grants, speaker fees, food and beverages, travel, royalties, and other forms of compensation.

Industry Total (2024)

$13.9B

across 1,925 companies

Boehringer Ingelheim RCV GmbH & Co KG Share

0.0%

#1117 by total payments

Companies with Similar Payment Volumes

Pharmaceutical companies with payment totals similar to Boehringer Ingelheim RCV GmbH & Co KG

Oculus Surgical Inc.

$127.1K 72 recipients

Southern Implants North America Inc

$127.2K 324 recipients

Reflow Medical Inc

$126.3K 1,044 recipients

FEMSelect Inc.

$126.2K 193 recipients

NextStep Arthropedix, LLC

$125.7K 36 recipients

ImpediMed, Inc.

$128.1K 97 recipients

Frequently Asked Questions

How much did Boehringer Ingelheim RCV GmbH & Co KG pay to physicians and hospitals in 2024? ▾
Boehringer Ingelheim RCV GmbH & Co KG made $126,893.79 in payments to physicians and hospitals in Program Year 2024, across 70 individual transactions. This represents 0.0% of all industry payments reported to CMS Open Payments.
How many physicians received payments from Boehringer Ingelheim RCV GmbH & Co KG? ▾
Averaging $10.6K per recipient, Boehringer Ingelheim RCV GmbH & Co KG's 2024 payments reached 12 physicians and teaching hospitals.
What types of payments did Boehringer Ingelheim RCV GmbH & Co KG make? ▾
3 categories of general payment make up Boehringer Ingelheim RCV GmbH & Co KG's reported activity, including consulting, meals, travel, and similar types. The largest general-payment category was "Compensation for Services Other Than Consulting" at $29.9K, representing 23.5% of the company's reported total.
How does Boehringer Ingelheim RCV GmbH & Co KG rank among pharmaceutical companies? ▾
By total payment amount, Boehringer Ingelheim RCV GmbH & Co KG sits at #1117 of 1,925 companies in the CMS Open Payments database for 2024.
What is the average payment size from Boehringer Ingelheim RCV GmbH & Co KG? ▾
In 2024, Boehringer Ingelheim RCV GmbH & Co KG averaged $1.8K per transaction across 70 transactions to 12 recipients.
Where does the payment data for Boehringer Ingelheim RCV GmbH & Co KG come from? ▾
This data comes from the CMS Open Payments program (Sunshine Act), which requires pharmaceutical and medical device companies to report payments and transfers of value to physicians and teaching hospitals. The data covers Program Year 2024.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch Editorial
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Boehringer Ingelheim RCV GmbH & Co KG's data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-25.